1. Treatment of early-stage Hodgkin lymphoma
Andreas Engert, John Raemaekers 
Seminars in Hematology 
Volume 53, Issue 3, Pages (July 2016)
DOI: /j.seminhematol
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Fig. 1
Evolution of radiotherapy in HL. Adapted from Yahalom, Lugano, © Yahalom, J.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Fig. 2
EORTC H8F trial. Freedom from treatment failure (FFTF) for patients with early favorable HL. From Ferme et al [9]. © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Fig. 3
HD7 trial for early favorable HL (FFTF). Reprinted from Engert A et al [10]. © 2007 American Society of Clinical Oncology. All rights reserved.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

5. Fig. 4
GHSG HD10 study. Weakest v strongest arm (FFTF). From Engert A et al [11]. © 2010 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

6. Fig. 5
GHSG HD13 trial. Progression-free survival. Reprinted with permission from Behringer et al [12].
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

7. Fig. 6
GHSG HD8 study. Early unfavorable HL (FFTF). Reprinted from Engert et al [13]. © 2003 American Society of Clinical Oncology. All rights reserved.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

8. Fig. 7
GHSG HD11 trial. Early unfavorable HL (FFTF). Reprinted from Eich et al [14]. © 2010 American Society of Clinical Oncology. All rights reserved.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

9. Fig. 8
GHSG HD14 trial. Early unfavorable HL (PFS). Reprinted from von Tresckow et al [15]. © 2012 American Society of Clinical Oncology. All rights reserved.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions

10. Fig. 9
Kaplan-Meier plots of progression-free survival. Included are data from patients with PET-negative findings who underwent randomization. The intention-to-treat analysis included 420 patients, and the per-protocol analysis included 392 patients. From Radford et al [30]. © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Seminars in Hematology  , DOI: ( /j.seminhematol )
Copyright © 2016 Elsevier Inc. Terms and Conditions